503B outsourcing facility
Also called Outsourcing facility, 503B compounder
A 503B outsourcing facility is a compounder that has chosen to register with the FDA under section 503B of the Federal Food, Drug, and Cosmetic Act, a category Congress created in 2013 after a deadly outbreak linked to contaminated compounded drugs. An outsourcing facility compounds sterile drugs and, unlike a 503A pharmacy, may supply them in response to an order from a hospital or clinic for office stock as well as on individual prescriptions.
In exchange, it carries heavier obligations. Outsourcing facilities must follow current good manufacturing practice (CGMP), are inspected by the FDA on a risk-based schedule, report adverse events and tell the FDA what they make. Their products are still compounded drugs: they are exempt from FDA approval, not FDA-approved.
Why it matters after 45
Injectable treatments common in midlife care, such as some weight-loss medications and peptides, are often prepared by outsourcing facilities. Knowing what the registration does and does not mean helps you read claims about where a preparation comes from, and why FDA policy on which substances 503B facilities may use matters.
Where it comes up
Related terms
References
- U.S. Food and Drug Administration. Information for Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities
- U.S. Food and Drug Administration. Human Drug Compounding Laws. https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Definitions here are educational and are not medical advice. They explain what a term means; the pages linked above cover what it means for you, and a clinician reviews your own results. Editorial & medical review policy · All glossary terms